Physician profile
Mohammed Razvi
NPI 1750728549
$1,117.98
in general payments reported to CMS, 2019-2025
10 companies · $387 in 2025
The $387 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $106 · 2023: $153 · 2024: $304 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.34 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $272.85 | 2019-2020 | |
| Teleflex LLC | $194.55 | 2025 | Barrigel |
| Immunitybio, INC. | $135.17 | 2025 | |
| Terumo Medical Corporation | $116.31 | 2023-2025 | Hydropearl, Glidewire, Azur Cx Detachable |
| Progenics Pharmaceuticals, INC. | $113.77 | 2024 | |
| Sumitomo Pharma America, INC. | $111.79 | 2024 | Orgovyx |
| Medtronic, INC. | $95.00 | 2023 | Interstim |
| Merit Medical Systems INC | $28.22 | 2025 | Convertx, Embosphere Microspheres |
| Siemens Medical Solutions USA, INC. | $27.21 | 2024 | Embozene |
| Urogen Pharma, INC. | $23.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Razvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.